ResQ Medical is an Israeli startup company established in August 2022 with the support of the Israel Innovation Authority (IIA) and Youdim Pharmaceuticals a private professional leading investor in the medical field. The company developed a safe, effective, cutting-edge device for treating Postpartum Hemorrhage (PPH).
Our goal is to become an essential tool in every delivery room & the first choice in the treatment of PPH and alleviate the risks and the potential complications to which millions of women each year are exposed during delivery.
RESQ-MEDICAL
Market and Business Opportunity
The global market for postpartum hemorrhage devices expected to exceed $1.35 billion by 2030, CAGR of 5.4% over the forecast period. Further, the increasing rate of complications in pregnancies is a major factor driving the demand for postpartum hemorrhage devices, thereby contributing to market growth. It is estimated that nearly 5% of women giving birth in the United States develop PPH after giving birth, meaning about 200,000 women a year in the US alone!
The Need
- Before undertaking surgical operations, an attempt is made to stop the bleeding using dedicated devices, from which the go to device today is the Uterine balloon Tamponade (UBT) , an expanding balloon that aims to control bleeding by compressing the intrauterine blood vessels.
- These solutions essentially work against the body’s natural mechanism of contracting the uterus to stop bleeding, resulting in a significant failure rate of 30%. The market is in need of an effective, reliable, easy-to-use, and affordable solution!
Alma
An innovative device which is attentive to the physiology and anatomy.
The mode of operation mimics the contraction of the uterus for stopping the bleeding as occurring naturally in any normal birth.
Advantages
Our approach with ALMA is to support the natural contraction of the uterus which in turn leads to the cessation of the bleeding as occurring naturally in any normal birth, and which doesn’t occur in the case of PPH.
This innovative approach contrasts with the medical devices used today, which are based on inserting and inflating a balloon inside the uterine cavity- causing the uterus to expend against the natural mechanism of the body.
Mimicking Natural Uterine Contraction to Control PPH:
- Facilitates uterine contraction to compress and close leaking blood vessels
Safe and Efficient: - The semi-flexible anatomical design supports natural uterine contractions, reducing recovery time
- Continuous low-level vacuum promotes controlled and safe uterine collapse
Simple and Intuitive Operation:
- Easy insertion and removal
- Cost-effective solution
Seeking
- Strategic collaboration
- Investment for IND
נגן וידאו
Alma operation step by step
THE TEAM
Dr. Itamar Dach, CEO, D.V.M., Co-founder
More than 17 years’ experience in the medical device arena, fulfilling a wide range of roles:Field marketing specialist, Upstream Marking-Philips Healthcare,Senior field service- Volcano,Product specialist-SyncRx,CRA and preclinical coordinator -Navotek Medical,CRE-Biocontrol Medical
Dr. Amnon Weichselbaum, CTO, Ph.D., Co-founder
Over 20 years of hands-on experience in the Israeli medical start-up industry Former CTO & Business Development Director at OFEK technological incubator,Migdal HaEmek, Israel.• CEO of Aqueduct Medical
• Co-founder of Fertiligent, CBF Medical, Bacterioscan, Ferticool
Prof. Michael Stark, M.D. Medical leader, Co-founder
Specialized in Obstetrics and Gynecology. In the years 1983-2000 he was the director of Ob/Gyn department of the Misgav Ladach Hospital in Jerusalem, and between 2001 and 2009 the chairman of Gynecology at the HELIOS, European Hospital Group.Currently, the President of the New European Surgical Academy (NESA), an international inter-disciplinary surgical academy. Prof. Stark was the scientific advisor of the European novel Tele-surgical system, scientific and medical advisor of the ELSAN, a 120-hospital group in France and is a guest scientist at the Charite’s University hospital in Berlin.
Efrat Herscovitch – CFO,BOD
With extensive experience in the area of Technological incubators, Efrat has over 20-years experience with start-up companies, having served in various financial positions at incubators. Prior joining TerraLab, she served in various finance positions as CFO and Finance controller in Israeli companies such as Eltam Technological Incubator, Naiot Technological Center, L.N. innovative Technology Ltd and has rendered financial services to the project companies during and post the incubation period
Dr. Roy Z. Mansano, M.D. Medical advisor
Double board certified in Obstetrician/Gynecologist and Maternal-Fetal Medicine Perinatology. Owner of the Comprehensive Maternal Fetal Medicine Center which provides care for patients throughout Los Angeles and Ventura counties with affiliations of 7 large medical centers including Tarzana Providence Cedar Sinai Medical Center, Olive-View UCLA, Medical Center and Los Robles Medical Center where he is the perinatal director. He received his medical degree from Technion-Israel Inst of Technology Faculty of Medicine and has been in practice for more than 20 years.
BOARD
New Northern Industrial Park, 1 Ha-Tsmikha St.,
Stern Building, Fl-3 Yokneam 2069207, Israel